PT-141 Dosage and Protocols

The FDA-approved prescribing information for Vyleesi includes specific pharmacokinetic-informed dosing restrictions that reflect the disconnect between half-life and duration of activity. • Administration is limited to no more than one dose per 24 hours and no more than 8 doses per month, despite the 2.7-hour half-life. These restrictions are based on clinical trial safety data showing that transient blood pressure increases (10-15 mmHg systolic) and nausea warrant a full 24-hour washout period between doses. • Onset of sexual desire effects begins within 30-60 minutes of injection, closely tracking the Tmax, but effects on desire and arousal persist for up to 24 hours, consistent with sustained MC4R signaling in hypothalamic circuits after the peptide has cleared from plasma. • The peptide should be administered at least 45 minutes before anticipated sexual activity. Unlike PDE5 inhibitors which require vascular arousal mechanisms, PT-141's central mechanism means the timing window is more flexible, the 24-hour effect window does not require precise timing.

Dosing details above reflect FDA-approved labeling and/or published clinical protocols. Always refer to the official drug label (linked above) for approved prescribing details, contraindications, and warnings.